Clinical Trials Directory

Trials / Completed

CompletedNCT03395548

Stability of the Microbiome in IBD and IBS

Stability of the Intestinal Microbiome in Patients Suffering From Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS) Under the Influence of an Osmotic Laxans

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
50 (actual)
Sponsor
Medical University of Graz · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

In this study the investigators aim to investigate the changes of the intestinal microbiome in three different cohorts (IBD, IBS, healthy) after applying the uniform disruptive factor of osmotic diarrhea induced by macrogol. The investigators hypothesis is that ill people will show more severe changes of the microbiome than healthy people and that these changes persist longer.

Detailed description

I

Conditions

Interventions

TypeNameDescription
DRUGMacrogolUsed drug: Macrogol (osmotic laxative)

Timeline

Start date
2017-08-25
Primary completion
2020-05-01
Completion
2020-05-01
First posted
2018-01-10
Last updated
2020-08-11

Locations

1 site across 1 country: Austria

Source: ClinicalTrials.gov record NCT03395548. Inclusion in this directory is not an endorsement.

Stability of the Microbiome in IBD and IBS (NCT03395548) · Clinical Trials Directory